| 5th Oct 2022 7:00 am |
EQS |
Director/PDMR Shareholding |
| 3rd Oct 2022 4:32 pm |
EQS |
Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022 |
| 3rd Oct 2022 4:31 pm |
EQS |
Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022 |
| 15th Sep 2022 7:01 am |
EQS |
Unaudited NAV for August 2022 |
| 15th Sep 2022 7:00 am |
EQS |
Unaudited NAV for August 2022 |
| 12th Aug 2022 7:00 am |
EQS |
Unaudited NAV for July 2022 |
| 12th Aug 2022 7:00 am |
EQS |
Unaudited NAV for July 2022 |
| 10th Aug 2022 6:05 pm |
EQS |
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer |
| 10th Aug 2022 6:05 pm |
EQS |
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer |
| 10th Aug 2022 5:46 pm |
EQS |
Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics |
| 10th Aug 2022 5:46 pm |
EQS |
Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics |
| 10th Aug 2022 7:01 am |
EQS |
Interim Results for the Six Months Ended 30 June 2022 |
| 10th Aug 2022 7:01 am |
EQS |
Arix Bioscience plc Announces Changes to Board of Directors |
| 10th Aug 2022 7:01 am |
EQS |
Arix Bioscience plc Announces Changes to Board of Directors |
| 10th Aug 2022 7:00 am |
EQS |
Interim Results for the Six Months Ended 30 June 2022 |
| 3rd Aug 2022 7:00 am |
EQS |
Notice of Results & Investor Presentation |
| 3rd Aug 2022 7:00 am |
EQS |
Notice of Results & Investor Presentation |
| 22nd Jul 2022 7:00 am |
EQS |
Unaudited NAV for June 2022 |
| 22nd Jul 2022 7:00 am |
EQS |
Unaudited NAV for June 2022 |
| 22nd Jun 2022 4:45 pm |
EQS |
Holding(s) in Company |
| 22nd Jun 2022 4:45 pm |
EQS |
Holding(s) in Company |
| 22nd Jun 2022 7:00 am |
EQS |
Notice of Investor Presentation |
| 22nd Jun 2022 7:00 am |
EQS |
Notice of Investor Presentation |
| 9th Jun 2022 7:00 am |
EQS |
Unaudited NAV for May 2022 |
| 9th Jun 2022 7:00 am |
EQS |
Unaudited NAV for May 2022 |
| 7th Jun 2022 4:45 pm |
EQS |
Result of Annual General Meeting 2022 |
| 12th May 2022 9:00 am |
RNS |
Communications with Shareholders |
| 12th May 2022 7:00 am |
RNS |
Publication of Annual Report & Notice of AGM |
| 11th May 2022 7:01 am |
EQS |
Unaudited NAV for April |
| 9th May 2022 3:29 pm |
EQS |
Clinical Development Update from Portfolio Company LogicBio |
| 5th May 2022 7:01 am |
EQS |
Financial Results for the Year Ended 31 December 2021 |
| 4th May 2022 6:39 pm |
RNS |
Statement Regarding Arix Bioscience plc |
| 4th May 2022 7:01 am |
EQS |
TR-1: Notification of major holdings |
| 29th Apr 2022 10:45 am |
EQS |
Unaudited NAV and Notice of Financial Results |
| 5th Apr 2022 4:29 pm |
EQS |
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia |
| 14th Mar 2022 11:32 am |
EQS |
Corporate update from portfolio company Harpoon Therapeutics |
| 25th Feb 2022 5:30 pm |
RNS |
Closed Period Notification |
| 24th Feb 2022 8:00 am |
RNS |
Company Secretary Change |
| 8th Feb 2022 7:20 am |
EQS |
Total Voting Rights |
| 2nd Feb 2022 1:06 pm |
EQS |
Arix Bioscience PLC: Clinical development update from portfolio company LogicBio |
